Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this China Phase I bridging study is to to evaluate the safety, tolerability
and pharmacokinetic profile of telatinib in China patients with advanced solid tumor